ArticleOpen veterinary journal2025
Retrospective evaluation of short- and medium-term therapeutic response to different immunosuppressive and dietary approaches in 148 dogs diagnosed with immunosuppressant-responsive enteropathy.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neutrophilic inflammatory enteropathy in 27 dogs: a retrospective descriptive study.Journal of veterinary internal medicine · 2026Article
- Rethinking clinical response criteria in trials of chronic enteropathy in dogs: what change is truly meaningful?Journal of veterinary internal medicine · 2026Article
- The Collaborative Collapse: Bile Acid Dysmetabolism as a Central Pathogenic Driver in Canine and Feline Multi-Systemic Disorders-From Mechanisms to Precision Therapeutics.Veterinary sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic intestinal inflammation in dogs is common worldwide; however, it can be very difficult to manage and predict clinical response to different treatment protocols. Aim: This retrospective analysis included 148 dogs with chronic intestinal inflammation with the aim of describing different treatment protocols and their impact on clinical response and identifying potential predictors of treatment failure. Methods: Of the 148 dogs, 53 were classified as having presumptive inflammatory protein-losing enteropathy (IRE-PLE). The factors associated with treatment failure were also analyzed. Clinical severity (CCECAI), serum albumin concentration, type of immunosuppressive therapy (prednisolone vs prednisolone in combination with cyclosporine or chlorambucil), type of diet (hydrolyzed protein, restricted antigen, highly digestible, restricted fat), and cobalamin supplementation were evaluated at diagnosis (T0) and after 1 (T1) and 6 (T6) months. CCECAI at T1 and T6 were used to evaluate the short- and medium-term response, respectively. Results: A total of 113 dogs (33.6% IRE-PLE) received prednisolone. Twenty-one dogs (28.6% IRE-PLE) received prednisolone and cyclosporine, whereas 14 dogs (64.3% IRE-PLE) received prednisolone and chlorambucil. Ninety-five (41% IRE-PLE) received cobalamin supplementation. Hydrolyzed protein and restricted antigen diets were most commonly prescribed. At T1 and T6, 79% and 59.5% of dogs were responders (24.8% and 15.9% IRE-PLE), and 21% and 27% (79.3% and 72.5% IRE-PLE) were nonresponders, respectively. The median CCECAI scores were 2 (IQR 4) and 0 (IQR 2) at T1 and T6, respectively. Conclusion: Most dogs showed favorable clinical outcomes, although a subset did not respond to treatment at short- and medium-term follow-up. Most deaths or euthanasia occurred within 1 month of diagnosis. The therapeutic response was not influenced by the type of immunosuppressive protocol, but rather by the presence of hypoalbuminemia, hypocobalaminemia, and the need for a home-cooked restricted-fat diet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.